ERBB2 and breast cancer: The accuracy of MRI for predicting residual tumor size was greatest in patients with the triple-negative phenotype or HER2-positive breast cancers, and a better correlation was noted in the triple-negative subtype with higher Ki-67 levels [8,25,26].